Qualigen Therapeutics Inc. (NASDAQ: QLGN) is 8.64% higher on its value in year-to-date trading and has touched a low of $2.87 and a high of $21.50 in the current 52-week trading range. The QLGN stock was last observed hovering at around $3.27 in the last trading session, with the day’s gains setting it 0.17% off its average median price target of $10.00 for the next 12 months. It is also 65.6% off the consensus price target high of $10.00 offered by 1 analysts, but current levels are 65.6% higher than the price target low of $10.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $3.44, the stock is 1.95% and -2.38% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.35 million and changing 5.20% at the moment leaves the stock -37.85% off its SMA200. QLGN registered -42.61% loss for a year compared to 6-month loss of -26.68%. The firm has a 50-day simple moving average (SMA 50) of $3.4191 and a 200-day simple moving average (SMA200) of $4.3563.
The stock witnessed a -9.17% gain in the last 1 month and extending the period to 3 months gives it a -37.48%, and is 8.64% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.38% over the week and 8.60% over the month.
Qualigen Therapeutics Inc. (QLGN) has around 5 employees, a market worth around $84.89M and $1.70M in sales. Distance from 52-week low is 19.86% and -84.00% from its 52-week high.
Qualigen Therapeutics Inc. (QLGN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Qualigen Therapeutics Inc. (QLGN) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Qualigen Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.13 with sales reaching $1.21M over the same period.The EPS is expected to grow by 71.10% this year.
Qualigen Therapeutics Inc. (QLGN) Top Institutional Holders
21 institutions hold shares in Qualigen Therapeutics Inc. (QLGN), with 2.52M shares held by insiders accounting for 10.91% while institutional investors hold 3.50% of the company’s shares. The shares outstanding are 26.71M, and float is at 21.15M with Short Float at 8.25%. Institutions hold 3.12% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 0.31 million shares valued at $1.55 million. The investor’s holdings represent 1.36% of the QLGN Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 0.31 million shares valued at $1.51 million to account for 1.33% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 66306.0 shares representing 0.29% and valued at over $0.33 million, while Citadel Advisors LLC holds 0.23% of the shares totaling 53687.0 with a market value of $0.27 million.
Qualigen Therapeutics Inc. (QLGN) Insider Activity
The most recent transaction is an insider purchase by Kruger Kurt H, the company’s Director. SEC filings show that Kruger Kurt H bought 4,000 shares of the company’s common stock on Dec 29 at a price of $2.94 per share for a total of $11740.0. Following the purchase, the insider now owns 10000.0 shares.
Qualigen Therapeutics Inc. disclosed in a document filed with the SEC on Nov 23 that Kruger Kurt H (Director) bought a total of 4,600 shares of the company’s common stock. The trade occurred on Nov 23 and was made at $3.46 per share for $15925.0. Following the transaction, the insider now directly holds 6000.0 shares of the QLGN stock.
Still, SEC filings show that on Nov 20, Kruger Kurt H (Director) acquired 1,400 shares at an average price of $3.55 for $4969.0. The insider now directly holds 1,400 shares of Qualigen Therapeutics Inc. (QLGN).